Respiratory

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate PRS-060/AZD1402
Targets

IL4-Rα

Partner

AstraZenica

Commercial Rights

Worldwide
Profit-Share Option

Discovery complete
Preclinical complete
Phase 1 complete
Phase 2 in progress
Candidate Proprietary Programs
Targets

n.d.

Partner

n/a

Commercial Rights

Worldwide

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate AstraZeneca Programs*
Targets

n.d.

Partner

AstraZeneca

Commercial Rights

Worldwide
Profit-Share Option

Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started
Candidate Genentech Programs**
Targets

n/a

Partner

Commercial Rights

Royalties

Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started

*4 additional respiratory programs in collaboration with AstraZeneca, 2 of which carry co-development and co-commercialization options for Pieris

**Collaboration includes 1 respiratory program and 1 ophthalmology program

Immuno-Oncology

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate Cinrebafusp Alfa (PRS-343)
Targets

HER2/4-1BB

Partner

n/a

Commercial Rights

Worldwide

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate PRS-344/S095012
Targets

PD-L1/4-1BB

Partner

Servier

Commercial Rights

U.S. Rights; Ex-U.S. Royalties

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate PRS-342/BOS-342
Targets

4-1BB/GPC3

Partner

Commercial Rights

Royalties

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate PRS-352
Targets

n.d.

Partner

Servier

Commercial Rights

Royalties

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started
Candidate Candidate Seagen Programs‡
Targets

n.d.

Partner

Commercial Rights

US Co-Promotion Option

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started

‡ 3 bispecific programs (1 active, 2 forthcoming) in collaboration with Seagen.

Programs that Stand up to Scrutiny

Our Scientific Advisory Board holds us to the highest standards of scientific practice.

View Advisory Board